These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 23942342

  • 1. A biopsychosocial model of interferon-alpha-induced depression in patients with chronic hepatitis C infection.
    Baranyi A, Meinitzer A, Stepan A, Putz-Bankuti C, Breitenecker RJ, Stauber R, Kapfhammer HP, Rothenhäusler HB.
    Psychother Psychosom; 2013; 82(5):332-40. PubMed ID: 23942342
    [Abstract] [Full Text] [Related]

  • 2. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity.
    Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpé S, Maes M.
    Mol Psychiatry; 2005 Jun; 10(6):538-44. PubMed ID: 15494706
    [Abstract] [Full Text] [Related]

  • 3. The role of anthranilic acid in the increase of depressive symptoms and major depressive disorder during treatment for hepatitis C with pegylated interferon-α2a and oral ribavirin.
    Pawlowski T, Pawlak D, Inglot M, Zalewska M, Marciniak D, Bugajska J, Janocha-Litwin J, Malyszczak K.
    J Psychiatry Neurosci; 2021 Jan 18; 46(1):E166-E175. PubMed ID: 33464780
    [Abstract] [Full Text] [Related]

  • 4. Asymmetric dimethylarginine responses during interferon-α-induced depression in patients with chronic hepatitis C infection.
    Baranyi A, Meinitzer A, Putz-Bankuti C, Stauber R, Kapfhammer HP, Rothenhäusler HB.
    Psychosom Med; 2014 Apr 18; 76(3):197-207. PubMed ID: 24608038
    [Abstract] [Full Text] [Related]

  • 5. [Impact of interferon alpha immunotherapy on tryptophan metabolism in patients with chronic hepatitis C. Results of a pilot studies on ten patients].
    Vignau J, Costisella O, Canva V, Imbenotte M, Duhamel A, Lhermitte M.
    Encephale; 2009 Oct 18; 35(5):477-83. PubMed ID: 19853722
    [Abstract] [Full Text] [Related]

  • 6. Quinolinic Acid Responses during Interferon-α-Induced Depressive Symptomatology in Patients with Chronic Hepatitis C Infection - A Novel Aspect for Depression and Inflammatory Hypothesis.
    Baranyi A, Meinitzer A, Breitenecker RJ, Amouzadeh-Ghadikolai O, Stauber R, Rothenhäusler HB.
    PLoS One; 2015 Oct 18; 10(9):e0137022. PubMed ID: 26368809
    [Abstract] [Full Text] [Related]

  • 7. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system.
    Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, Almerighi C, Verkerk R, Meltzer H, Maes M.
    J Clin Psychopharmacol; 2002 Feb 18; 22(1):86-90. PubMed ID: 11799348
    [Abstract] [Full Text] [Related]

  • 8. Somatization, but not depression, is characterized by disorders in the tryptophan catabolite (TRYCAT) pathway, indicating increased indoleamine 2,3-dioxygenase and lowered kynurenine aminotransferase activity.
    Maes M, Galecki P, Verkerk R, Rief W.
    Neuro Endocrinol Lett; 2011 Feb 18; 32(3):264-73. PubMed ID: 21712776
    [Abstract] [Full Text] [Related]

  • 9. Lack of association of indoleamine 2,3-dioxygenase polymorphisms with interferon-alpha-related depression in hepatitis C.
    Galvão-de Almeida A, Quarantini LC, Sampaio AS, Lyra AC, Parise CL, Paraná R, de Oliveira IR, Koenen KC, Miranda-Scippa A, Guindalini C.
    Brain Behav Immun; 2011 Oct 18; 25(7):1491-7. PubMed ID: 21693183
    [Abstract] [Full Text] [Related]

  • 10. The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): relevance for depression - and other conditions characterized by tryptophan depletion induced by inflammation.
    Maes M, Mihaylova I, Ruyter MD, Kubera M, Bosmans E.
    Neuro Endocrinol Lett; 2007 Dec 18; 28(6):826-31. PubMed ID: 18063923
    [Abstract] [Full Text] [Related]

  • 11. Alterations in the metabolism of tryptophan in patients with chronic hepatitis C six months after pegylated interferon-α 2a treatment.
    Pawlowski T, Malyszczak K, Inglot M, Zalewska M, Radkowski M, Laskus T, Pawlak D.
    Psychoneuroendocrinology; 2018 Nov 18; 97():1-7. PubMed ID: 29990677
    [Abstract] [Full Text] [Related]

  • 12. Depressive symptoms in patients with hepatitis C treated with pegylated interferon alpha therapy: a 24-week prospective study.
    Pavlović Z, Delić D, Marić NP, Vuković O, Jašović-Gašić M.
    Psychiatr Danub; 2011 Dec 18; 23(4):370-7. PubMed ID: 22075738
    [Abstract] [Full Text] [Related]

  • 13. Factors influencing long-term changes in mental health after interferon-alpha treatment of chronic hepatitis C.
    Schmidt F, Janssen G, Martin G, Lorenz R, Loeschke K, Soyka M, Folwaczny C, Schaefer M.
    Aliment Pharmacol Ther; 2009 Nov 15; 30(10):1049-59. PubMed ID: 19691667
    [Abstract] [Full Text] [Related]

  • 14. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.
    Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, Heldwein W, Soyka M, Grunze H, Koenig A, Loeschke K.
    Hepatology; 2003 Feb 15; 37(2):443-51. PubMed ID: 12540795
    [Abstract] [Full Text] [Related]

  • 15. [Hepatitis C, interferon a and depression: main physiopathologic hypothesis].
    Vignau J, Karila L, Costisella O, Canva V.
    Encephale; 2005 Feb 15; 31(3):349-57. PubMed ID: 16142050
    [Abstract] [Full Text] [Related]

  • 16. Depressive symptoms as a side effect of Interferon-α therapy induced by induction of indoleamine 2,3-dioxygenase 1.
    Murakami Y, Ishibashi T, Tomita E, Imamura Y, Tashiro T, Watcharanurak K, Nishikawa M, Takahashi Y, Takakura Y, Mitani S, Fujigaki H, Ohta Y, Kubo H, Mamiya T, Nabeshima T, Kim HC, Yamamoto Y, Saito K.
    Sci Rep; 2016 Jul 20; 6():29920. PubMed ID: 27436416
    [Abstract] [Full Text] [Related]

  • 17. [Depressive disorders and symptoms accompanying pegylated interferon alpha and ribavirin treatment of chronic hepatitis C patients].
    Pawełczyk T, Białkowska J, Jabłkowski M, Pawełczyk A, Strzelecki D, Rabe-Jabłońska J, Dworniak D.
    Pol Merkur Lekarski; 2008 Jun 20; 24(144):516-20. PubMed ID: 18702333
    [Abstract] [Full Text] [Related]

  • 18. Neurotoxic and neuroprotective metabolites of kynurenine in patients with renal cell carcinoma treated with interferon-alpha: course and relationship with psychiatric status.
    Van Gool AR, Verkerk R, Fekkes D, Bannink M, Sleijfer S, Kruit WH, van der Holt B, Scharpé S, Eggermont AM, Stoter G, Hengeveld MW.
    Psychiatry Clin Neurosci; 2008 Oct 20; 62(5):597-602. PubMed ID: 18950381
    [Abstract] [Full Text] [Related]

  • 19. [Interferon α therapy in patients with chronic hepatitis C infection: biopsychosocial consequences].
    Baranyi A, Meinitzer A, Stepan A, Matejka J, Stauber R, Kapfhammer HP, Rothenhäusler HB.
    Nervenarzt; 2012 Sep 20; 83(9):1169-77. PubMed ID: 22033579
    [Abstract] [Full Text] [Related]

  • 20. Treatment with interferon-alpha (IFN alpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN alpha-induced depressive and anxiety symptoms and immune activation.
    Maes M, Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, Almerighi C, Meltzer H.
    Mol Psychiatry; 2001 Jul 20; 6(4):475-80. PubMed ID: 11443537
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.